Title: A Phase 1b and 2a Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination With PLX3397 or Sunitinib (Sutent®) in Patients With Advanced Solid Tumors and Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated With Imatinib Mesylate/KIT-Directed Tyrosine Kinase Inhibitor (TKI) Therapy1
Principal Investigators: None listed
Description: For this non-randomized, open-label phase 1b/2 study, researchers are evaluating the safety and efficacy of PLX9486, a TKI of c-Kit, in combination with pexidartinib (PLX3397) and sunitinib among patients with GIST. As KIT is often mutated in GISTs, this combination is predicted to halt cancer cell proliferation.
Continue Reading
This study has 7 arms: part 1, the dose escalation arm for determining the maximum tolerated dose of PLX9486, and 6 arms of part 2, in which patients will be stratified by several variables.
The primary outcomes are safety, overall response rate, progression-free survival, overall survival, and pharmacokinetics of PLX9486; secondary outcomes include duration of response.
For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02401815.
Status: This study is open and recruiting patients as of October 26, 2017.
This study is sponsored by Plexxikon.
Reference
- Clinicaltrials.gov. PLX9486 as a single agent and in combination with PLX3397 or PLX9486 with sunitinib in patients with advanced solid tumors. NCT02401815. https://clinicaltrials.gov/ct2/show/NCT02401815. Accessed October 26, 2017.
